1. |
Metoclopramide"primary agent"for migraine in emergency departments |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
In an attempt to increase the US supply of flu vaccine,*a clinical trial of Fluarix has been initiated |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
Cisplatin-based chemotherapy warranted in advanced NSCLC |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
Tegaserod improves QOL, cost effective in IBS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 5-6
&NA;,
Preview
|
|
摘要:
Irritable bowel syndrome (IBS) is a chronic, recurring disease affecting 10−20% of the US population. It is a multifaceted disorder, the exact cause of which is unknown, and is characterised by abdominal pain or discomfort, bloating and abnormal bowel function, resulting in chronic episodes of diarrhoea, constipation, or both in alternation. The burden of IBS on an individual can range from a mild inconvenience to severe debilitation, compounded by its unpredictability. As such, the disorder can have a broad and significant effect on patients' quality of life (QOL), controlling many aspects of their emotional, social and professional life. There is no known cure for IBS, and effective therapy remains a challenge. However, as the prevalence and impact of IBS becomes more well known, the medical community looks to new types of treatments for the disorder. Tegaserod [Zelnorm; Novartis], an indole carboxaldehyde derivative, is a selective serotonin4receptor partial agonist which targets receptors located throughout the GI tract. The agent is approved for use among patients with IBS whose primary bowel symptom is constipation, and has been shown in clinical trials to provide significant improvement in global IBS symptoms, and to be generally well tolerated. The effect of tegaserod on IBS patients' QOL, and the cost effectiveness of the drug, were assessed in two studies presented at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Hamburg, Germany; October 2004]. Both the studies were funded by Novartis, with which some of the researchers were affiliated.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
Elderly patients in Canada frequently use benzodiazepines for a longer period than recommended, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
Undertreatment common among elderly in assisted-living setting |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
Once-daily telavancin*shows promising activity in the treatment of complicated Gram-positive skin and skin structure infections (cSSSIs), |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
Febuxostat: a new gout therapy flares up |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 9-10
S Sullivan,
Preview
|
|
摘要:
Febuxostat [TEI 6720, TMX 67] is an effective treatment for patients with gout, according to studies presented at the 68th Annual Scientific Meeting of the American College of Rheumatology [San Antonio, US; October 2004]. Results from phase III studies showed that patients receiving febuxostat had lower serum uric acid levels and hence fewer gout flares, compared with allopurinol-treated patients. Long-term data from a phase II study indicated that febuxostat maintains reduced uric acid levels for up to 2 years. Furthermore, febuxostat was well tolerated in these studies, which included patients with an intolerance to allopurinol and patients with hepatic impairment.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
The p53 gene therapy Advexin has demonstrated positive results in locally-advanced breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
Paroxetine effective in childhood/adolescent OCD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1468,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|